
February 15 marked International Childhood Cancer Day. In recognition, we’re spotlighting Professor Eran Elinav, an expert in childhood leukemia. Childhood acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. While treatments have improved survival rates, many children experience severe side effects from chemotherapy, such as life-threatening infections or damage to vital organs. Identifying which children are at higher risk for these complications even before treatment is administered is a major unresolved challenge, leaving room for improvement in predicting and preventing these adverse events. Dr. Elinav’s research explores how the gut microbiome, the community of bacteria and other microorganisms in our digestive system, may help predict which children are more likely to experience severe treatment side effects. Using advanced computational tools, he and his team will analyze the microbiome to find patterns linked to adverse events. These patterns will then be used to develop personalized prediction models.




